Clover Biopharmaceuticals Ltd. · HKEX:2197

Clover Biopharmaceuticals — Corporate Update (January 2026)

28 slides from Clover Biopharmaceuticals's corporate update, January 2026

  1. Slide 1: Clover Biopharmaceuticals: Corporate Overview

    Clover Biopharmaceuticals: Corporate Overview RSV hMPV PIV3 January 2026

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate,"

  3. Slide 3: Executive Summary

    Executive Summary Clover is Developing Potential Global First-in-Class and Best-in-Class RSV + hMPV ± PIV3 Combination Vaccines (Phase 2 Ongoing) with the Potential Ability to Re-Vaccinate Individuals Previously Receiving Approved RSV Vaccines to Restore and Broaden Protection Recent Milestones & Ca

  4. Slide 4: Clover's Trimer-Tag Technology Platform for Vaccine Development

    Clover’s Trimer-Tag Technology Platform for Vaccine Development ▪ Highly Differentiated Vaccine Technology Platform: The only technology platform globally for producing recombinant covalently-trimerized antigens utilizing a human-derived trimerization tag; the use of covalent bond enables stable nat

  5. Slide 5: Trimer-Tag: A Safe, Potent & Validated Vaccine Platform

    Trimer-Tag: A Safe, Potent & Validated Vaccine Platform Extensive Clinical Experience Globally Endorsed by Leading Scientific Community  40,000+ Doses Administered Across 9 Countries & 6 Continents  Received US$ 397 Million Funding from to Support  Experience in Broad Population Groups (Elderly,

  6. Slide 6: RSV is a Validated Blockbuster Market; Expansion is Dependent on Addressing 2 Unmet Needs

    RSV is a Validated Blockbuster Market; Expansion is Dependent on Addressing 2 Unmet Needs 2 Key Unmet Needs & Opportunities to Unlock RSV Market Expansion: RSV  RSV Vaccines Have Generated ~US$ 4 Billion Product Sales in First 2 Years of Launch (2023-2024) Opportunity to Increase Uptake & Optimize

  7. Slide 7: $10 Billion+ Potential Peak Sales Globally for RSV Combo Vaccines with Ability to Re-Vaccinate

    $10 Billion+ Potential Peak Sales Globally for RSV Combo Vaccines with Ability to Re-Vaccinate Illustrative Estimated Peak Annual Doses in the U.S. for RSV Combination Vaccines ≥15M $10 Billion+ Potential Global Peak Sales for RSV Doses/Year Combination Vaccines with the Ability to Re-Vaccinate (1)

  8. Slide 8: Sanofi Acquires ViceBio for Up to $1.6 Billion Based on RSV-hMPV Combo Phase 1 Data

    Sanofi Acquires ViceBio for Up to $1.6 Billion Based on RSV-hMPV Combo Phase 1 Data Acquires Announced July 22nd, 2025 Acquisition Blockbuster Acquisition Based on ViceBio’s Date Phase 1 RSV-hMPV Combination Clinical Data Closed December 4th, 2025 Further Validates Significant Global Unmet Need and

  9. Slide 9: Prior Phase 1 Clinical Validation of Clover's RSV PreF (SCB-1019) Versus GSK (AREXVY)

    Australia Prior Phase 1 Clinical Validation of Clover’s RSV PreF (SCB-1019) Versus GSK (AREXVY) – Oct 2024 Phase 1 Demonstrated Best-in-Class Combined Immunogenicity & Tolerability Profile as an Initial Dose in RSV Vaccine-Naïve Older Adults, for Non-Adjuvanted SCB-1019 (Clover RSV PreF) Head-to-Hea

  10. Slide 10: Clover has Achieved Stable PreF-Trimer Conformations for its hMPV and PIV3 Antigens

    Clover has Achieved Stable PreF-Trimer Conformations for its hMPV and PIV3 Antigens Leveraged RSV PreF & Trimer-Tag Cryo-EM Structures for Clover’s hMPV and PIV3 PreF Antigens Resolved (<3Å Resolution) Platform Experience to Develop Trimeric hMPV and PIV3 Antigens Clover hMPV PreF-Trimer Clover PIV3

  11. Slide 11: Results Announced from Two Ongoing Phase 1 Clinical Trials (Oct-2025)

    Results Announced from Two Ongoing Phase 1 Clinical Trials (Oct-2025) RSV hMPV PIV3 Phase 1: RSV-hMPV-PIV3 Combination Vaccines RSV Phase 1: RSV Re-Vaccination SCB-1022 (RSV-hMPV) SCB-1019 (RSV) Australia Non-Adjuvanted U.S. Non-Adjuvanted Enrolled Enrolling Older Adults SCB-1033 (RSV-hMPV-PIV3) Old

  12. Slide 12: Phase 1 Immunogenicity Results (RSV and hMPV)

    Australia RSV hMPV PIV3 Phase 1 Immunogenicity Results (RSV and hMPV) Phase 1 Potential Best-In-Class RSV and hMPV Neutralizing Antibody (nAb) Responses for SCB-1022 and SCB-1033, with No Immune Interference on RSV ~6-8 Fold Increases in RSV nAbs ~6-9 Fold Increases in hMPV nAbs RSV RSV Neutralizing

  13. Slide 13: Phase 1 Immunogenicity Results (PIV3)

    Australia RSV hMPV PIV3 Phase 1 Immunogenicity Results (PIV3) Phase 1 Potential Best-In-Class PIV3 Neutralizing Antibody (nAb) Responses for SCB-1033, Driven by ≥10-Fold Increases in PIV3 PreF-Specific Antibodies ~4-Fold Increases in Total PIV3 nAbs for SCB-1033 PIV3 PIV3 Neutralizing Antibodies (GM

  14. Slide 14: Phase 1 Safety & Tolerability Results

    Australia RSV hMPV PIV3 Phase 1 Safety & Tolerability Results Phase 1 Potential Best-in-Class Safety & Tolerability Profiles for SCB-1022 and SCB-1033 Local and Systemic AEs for SCB-1022 (RSV-hMPV) and SCB-1033 (RSV-hMPV-PIV3) were Generally Mild and Comparable to SCB-1019 (RSV) ▪ Expected to Compar

  15. Slide 15: Re-Vaccination Issues Observed for Currently Approved RSV Vaccines

    Re-Vaccination Issues Observed for Currently Approved RSV Vaccines, Despite Waning Efficacy of Initial Dose An Incremental ~1.5x Higher nAb Response for Re-Vaccination with SCB-1019 Compared to AREXVY May be Able to Restore Peak Levels of nAbs & Protection % of Peak RSV Neutralizing Antibody Titers

  16. Slide 16: Phase 1 RSV Re-Vaccination Immunogenicity Results (Interim Analysis)

    U.S. RSV Phase 1 RSV Re-Vaccination Immunogenicity Results (Interim Analysis) Phase 1 ≥1.6x Higher Trend in RSV nAb Responses Observed for SCB-1019 Compared Head-to-Head Versus AREXVY Re-Vaccination Geometric Mean Fold Rises % of Subjects With (GMFRs) ≥2-Fold Increase 1.6-1.8x Higher Trend in RSV nA

  17. Slide 17: Phase 2 Trial Initiated in Jan 2026; Strengthens First-in-Class Positioning

    RSV hMPV PIV3 Phase 2 Trial Initiated in Jan 2026; Strengthens First-in-Class Positioning Australia Phase 2 RSV hMPV PIV3 Phase 2: RSV-hMPV-PIV3 Combination Vaccines  Phase 2 Initiation in January 2026 Strengthens SCB-1022 (RSV-hMPV) Non-Adjuvanted Clover’s First-in-Class Potential Australia Enroll

  18. Slide 18: Trimer-Tag Platform has Potential To Address ~75% of Viral Respiratory Disease Burden in Elderly

    Trimer-Tag Platform has Potential To Address ~75% of Viral Respiratory Disease Burden in Elderly Annual Disease Burden of Respiratory Viruses Trimer-Tag Platform Opportunity for Respiratory Combination Vaccines in Elderly in Elderly Population in U.S. (Est. Hospitalizations per 100,000 Persons) SCB-

  19. Slide 19: Appendix

    Appendix Page 19

  20. Slide 20: Dozens of Trimeric Antigen Targets for Potential Vaccine Development

    Dozens of Trimeric Antigen Targets for Potential Vaccine Development; Differentiated Proof-of-Concept for Trimer-Tag has been Demonstrated for 10+ Viruses Naturally-trimeric Structure Surface Antigens of Coronavirus (CoV) Influenza (Flu) RSV Shingles (VZV) CMV Herpes (HSV) Epstein-Barr (EBV) Viruses

  21. Slide 21: Trimer-Tag: Robust Safety Database Established, Including COVID-19 Global Phase 3 Study

    Trimer-Tag: Robust Safety Database Established, Including COVID-19 Global Phase 3 Study Belgium Brazil Colombia Philippines S. Africa  No Significant Safety Concerns Identified in COVID-19 (SCB-2019 + CpG 1018/Alum) Global Phase 2/3 Study in >15,000 Subjects Receiving >30,000 Doses Source: DOI: 10.

  22. Slide 22: Trimer-Tag: Robust Safety Database Established, Including COVID-19 Global Phase 3 Study

    Trimer-Tag: Robust Safety Database Established, Including COVID-19 Global Phase 3 Study Belgium Brazil Colombia Philippines S. Africa  No Significant Safety Concerns Identified in COVID-19 (SCB-2019 + CpG 1018/Alum) Global Phase 2/3 Study in >15,000 Subjects Receiving >30,000 Doses Source: DOI: 10.

  23. Slide 23: Preclinical Data (mAb Binding Affinity): Clover RSV PreF (SCB-1019) Versus GSK (AREXVY)

    Preclinical Data (mAb Binding Affinity): Clover RSV PreF (SCB-1019) Versus GSK (AREXVY)  Clover’s RSV PreF Demonstrates Differentiated and Stronger Binding Affinity than GSK (AREXVY) Against mAbs at Highly Potent Neutralization Sites (Site V, Site III) Binding Affinity of PreF Antigens to Potent mA

  24. Slide 24: Prior Phase 1 Clinical Validation of Clover's RSV PreF (SCB-1019) Versus GSK (AREXVY) – Oct 2024

    Aus Ph1 Prior Phase 1 Clinical Validation of Clover’s RSV PreF (SCB-1019) Versus GSK (AREXVY) – Oct 2024 (2024)  SCB-1019 Elicited Durable Site Ø /V-Specific NAb Responses + Observed Trend in Fewer Binding (Non-Neutralizing) Antibodies Note: Sites Ø +V Comprise >60% of Highly-Potent RSV Neutralizin

  25. Slide 25: Respiratory PreF Combo Vaccine (RSV + hMPV + PIV) Opportunity

    Respiratory PreF Combo Vaccine (RSV + hMPV + PIV) Opportunity ▪ Total Disease Burden of Combo (RSV+hMPV+PIV) is similar or greater than Flu Globally; combination vaccine is a compelling opportunity & unmet need ▪ Directly leveraging Clover’s RSV experience to develop ‘Respiratory Combo Vaccines’ acr

  26. Slide 26: Clover-Sponsored Epidemiology Pilot Study in China ('24-'25 Season)

    RSV hMPV PIV3 Clover-Sponsored Epidemiology Pilot Study in China (‘24-’25 Season) ▪ Pilot Study Enrolled ~1,100 Children Aged 2-5 Years in 2 Provinces (Northern China + Southern China) ▪ Surveillance for PCR-Confirmed Symptomatic ARI and LRTD from ~OCT-2024 to ~APR-2025 % of All LRTD Cases Collected

  27. Slide 27: AstraZeneca (Icosavax) IVX-A12 (RSV-hMPV Combo) – Phase 1/2 Results for hMPV NAbs

    AstraZeneca (Icosavax) IVX-A12 (RSV-hMPV Combo) – Phase 1/2 Results for hMPV NAbs ▪ IVX-A12 (RSV-hMPV Combo) Induced ~2.5-3.1x GMFRs in hMPV-A NAbs and ~2.4-2.8x GMFRs in hMPV-B NAbs in Phase 1 and Phase 2 Clinical Trials in Older Adults ▪ These Phase 1/2 Results in Older Adults were Supportive of A

  28. Slide 28: PIV3 Neutralizing Antibodies – Background & Overview of Published Peer-Reviewed Literature

    PIV3 Neutralizing Antibodies – Background & Overview of Published Peer-Reviewed Literature ▪ PIV3 HN Antibodies are Immuno-Dominant in Baseline (Unvaccinated) Human Sera (Low Levels of PIV3 PreF Neutralizing Antibodies are Detected in Baseline [Unvaccinated] Human Sera) ▪ However, PIV3 PreF Antibodi

Clover Biopharmaceuticals — Corporate Update (January 2026) on 6ix